Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Emilie S. Andersen; A. Lund; J. I. Bagger; C Andreasen; MF Grøndahl; Carolyn F. Deacon; Bolette Hartmann; Jens Juul Holst; Filip Krag Knop; Tina Vilsbøll Lauritsen

doi:10.1111/dom.13321

Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Emilie S. Andersen, A. Lund, J. I. Bagger, C Andreasen, MF Grøndahl, Carolyn F. Deacon, Bolette Hartmann, Jens Juul Holst, Filip Krag Knop, Tina Vilsbøll Lauritsen

Research output: Contribution to journal › Journal article › Research › peer-review

3 Citations (Scopus)

Original language	English
Journal	Diabetes, Obesity and Metabolism
Volume	20
Issue number	8
Pages (from-to)	1937-1943
ISSN	1462-8902
DOIs	https://doi.org/10.1111/dom.13321
Publication status	Published - Aug 2018

Access to Document

10.1111/dom.13321

Cite this

Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C., Grøndahl, MF., Deacon, C. F., Hartmann, B., Holst, J. J., Knop, F. K., & Lauritsen, T. V. (2018). Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, Obesity and Metabolism, 20(8), 1937-1943. https://doi.org/10.1111/dom.13321

Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? / Andersen, Emilie S.; Lund, A.; Bagger, J. I.; Andreasen, C; Grøndahl, MF; Deacon, Carolyn F.; Hartmann, Bolette ; Holst, Jens Juul ; Knop, Filip Krag ; Lauritsen, Tina Vilsbøll.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 8, 08.2018, p. 1937-1943.

Research output: Contribution to journal › Journal article › Research › peer-review

Andersen, ES, Lund, A, Bagger, JI, Andreasen, C, Grøndahl, MF, Deacon, CF , Hartmann, B , Holst, JJ , Knop, FK & Lauritsen, TV 2018, 'Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?', Diabetes, Obesity and Metabolism, vol. 20, no. 8, pp. 1937-1943. https://doi.org/10.1111/dom.13321

Andersen, Emilie S. ; Lund, A. ; Bagger, J. I. ; Andreasen, C ; Grøndahl, MF ; Deacon, Carolyn F. ; Hartmann, Bolette ; Holst, Jens Juul ; Knop, Filip Krag ; Lauritsen, Tina Vilsbøll. / Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20, No. 8. pp. 1937-1943.

@article{631116d895cf4875a4685b2fbc50d8bb,

title = "Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?",

author = "Andersen, {Emilie S.} and A. Lund and Bagger, {J. I.} and C Andreasen and MF Gr{\o}ndahl and Deacon, {Carolyn F.} and Bolette Hartmann and Holst, {Jens Juul} and Knop, {Filip Krag} and Lauritsen, {Tina Vilsb{\o}ll}",

year = "2018",

month = aug,

doi = "10.1111/dom.13321",

language = "English",

volume = "20",

pages = "1937--1943",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",